Hong Kong’s CK Life To Spin Off U.S. R&D Unit Polynoma, Keep Control
This article was originally published in PharmAsia News
Executive Summary
Hong Kong’s CK Life Sciences International intends to establish its U.S.-based subsidiary, Polynoma, as a separate company for research and development, including work on a vaccine for melanoma set to enter Phase III trials.